Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Thalidomide evaluated for toxic epidermal necrolysis and found detrimental

Dec. 10, 1998

Abgenix initiates a phase I/II clinical trial in patients with psoriasis

Dec. 3, 1998

Diane-35 now available in Canada for treatment of acne

Dec. 2, 1998

SA-9499 identified as potent and selective LTA4 hydrolase inhibitor at Santen

Nov. 27, 1998

Zileuton trials recommended for new indication: atopic dermatitis

Nov. 27, 1998

Continued positive results with fexofenadine in patients with CIU

Nov. 27, 1998

Organogenesis completes patient enrollment in Apligraf diabetic foot ulcer trial

Nov. 19, 1998

Positive phase III clinical trial results received for Olux

Nov. 12, 1998

Team from Angiotech demonstrates paclitaxel's potential as an antipsoriatic

Nov. 12, 1998

Idec Pharmaceuticals: Q3 1998 highlights

Nov. 4, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...